BIOTRICITY INC.

For the period ended Mar 31, 2026. Filed Jul 14, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2026 · Filed Jul 14, 2026

BTCY$0.06+7.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

	Year Ended March 31, 2026	Year Ended March 31, 2025
	$	$
REVENUE	15,998,239	13,790,294
Cost of Revenue	3,049,441	3,225,803
GROSS PROFIT	12,948,798	10,564,491
EXPENSES
Selling, general and administrative expenses	8,493,365	10,857,797
Research and development expenses	2,764,197	2,155,660
TOTAL OPERATING EXPENSES	11,257,562	13,013,457
INCOME (LOSS) FROM OPERATIONS	1,691,236	(2,448,966)
Other income/(expense) [Note 3]	159,978	(78,569)
Interest expense	(3,361,950)	(3,262,038)
Gain/(Loss) upon convertible promissory notes conversion and redemption [Note 8]	19,842	(137,934)
Accretion and amortization expenses	(745,896)	(1,939,816)
Change in fair value of derivative liabilities [Note 8]	(167,349)	(553,856)
NET LOSS BEFORE INCOME TAXES	(2,404,139)	(8,421,179)
Income taxes	—	—
NET LOSS BEFORE DIVIDENDS	(2,404,139)	(8,421,179)
Preferred Stock Dividends	(724,319)	(466,141)
Deemed Dividend	—	(3,054,680)
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	(3,128,458)	(11,942,000)
Translation adjustment	(35,547)	113,414
COMPREHENSIVE LOSS	(3,164,005)	(11,828,586)
LOSS PER SHARE, BASIC AND DILUTED	(0.115)	(0.555)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING	27,304,317	21,524,884

BIOTRICITY, INC.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.